

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

: 10/616,692

Applicant : Jodi Nelson

Filed : September 20, 2005

Title : Compositions and Methods for the Treatment of Parkinson's

Disease and Tardive Dyskinesias

Group Art Unit : 1614

Confirmation No : 1639

Examiner : Dwayne C. Jones

Docket No. : 47-00 B Customer No. : 23713

500e 140. . 20715

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage

as Express Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450 EV642818313US

On November 17, 2005

STEPHANIE LOTWIS

## RESPONSE TO REQUIREMENT FOR RESTRICTION

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement of September 1, 2005, applicants elect Group II, claims 1-13, drawn to a method of making and using a pharmaceutical, with traverse. The elected species is treating drug-induced dyskinesias with chloroquine phosphate and cimetidine. It is understood that if the Examiner finds this species allowable, he will examine the remaining species.

It is submitted that the Restriction Requirement is improper and should be withdrawn.

With respect to Groups II through V, claims 1-33, these allegedly separate inventions are all classified in the same class and subclass, and thus no undue burden is imposed on the Office by searching and examining them together.

With respect to division of Group I from Groups II-V, the Office Action alleges that the process for using the product as claimed can be practiced with another materially different product, such as with the administration of L-Dopa or deprenyl. This is incorrect.

Application No. 10/616,692

Response to Requirement for Restriction dated November 17, 2005

Reply to Office Action of September 1, 2005

The process for using the product as claimed requires using the compositions specified in

the claims.

With respect to division between Groups II and III-V, the Office Action alleges that

the inventions are not disclosed as capable of use together and they have different modes

of operation, different functions, or different effects. The Office Action states:

In the instant case the different inventions for example a method of

treating an ailment of a psychotic disease schizophrenia, as in claim

14, not only has different modes of operation than treating a movement

disorder, such as Parkinson's disease, as in claim 9, and also is not

required to treat both ailments at once, which shows that these

inventions, as well as the inventions of Groups IF and V, are in fact

capable of not being used together.

To the extent this statement is understood, it is pointed out that the Office Action

provides no reasoning why it should not be possible to treat both conditions together if a

patient were suffering from both conditions.

Withdrawal of the Restriction Requirement is respectfully requested.

A Petition for Extension of Time of two months accompanies this Response together

with a check in the amount of \$225.00. It is believed that this Response does not

necessitate the payment of any additional fees under 37 C.F.R. 1.16-1.17. If the amount

submitted is incorrect, however, please charge the necessary amount for this Response or

any extension of time required to Deposit Account No. 07-1969.

Respectfully submitted,

Elle P. Winner

Ellen P. Winner

Reg. No. 28,547

GREENLEE, WINNER AND SULLIVAN, P.C.

4875 East Pearl Circle, Suite 200, Boulder, CO 80301

Phone (303) 499-8080 Fax (303) 499-8089

sl: November 17, 2005

Docket 47-00B

2